Noncovalent SARS-CoV-2 main protease inhibitors targeting the catalytic dyad and primed substrate binding subsites.
- DOI
- 10.1039/d6md00401f
- Published
- 2026 Sep 1
- Container
- RSC medicinal chemistry
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1039/d6md00401f,
title = {Noncovalent SARS-CoV-2 main protease inhibitors targeting the catalytic dyad and primed substrate binding subsites.},
author = {Bhandari D and Kovalevskaya K and Coates L and Jonsson CB and Parvathareddy J and Weiss KL and Aniana A and Louis JM and Bonnesen PV and Kovalevsky A},
year = {2026},
journal = {RSC medicinal chemistry},
doi = {10.1039/d6md00401f},
url = {https://doi.org/10.1039/d6md00401f}
}RIS
TY - JOUR TI - Noncovalent SARS-CoV-2 main protease inhibitors targeting the catalytic dyad and primed substrate binding subsites. AU - Bhandari D AU - Kovalevskaya K AU - Coates L AU - Jonsson CB AU - Parvathareddy J AU - Weiss KL AU - Aniana A AU - Louis JM AU - Bonnesen PV AU - Kovalevsky A PY - 2026 JO - RSC medicinal chemistry DO - 10.1039/d6md00401f UR - https://doi.org/10.1039/d6md00401f ER -
APA
D, B., K, K., L, C., CB, J., J, P., KL, W., A, A., JM, L., PV, B., & A, K. (2026). Noncovalent SARS-CoV-2 main protease inhibitors targeting the catalytic dyad and primed substrate binding subsites.. RSC medicinal chemistry. https://doi.org/10.1039/d6md00401f
Source records
- pubmed · retrieved 2026-09-26T07:17:11.455Z
- europe-pmc · retrieved 2026-09-26T07:17:11.461Z